<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531427</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3025</org_study_id>
    <nct_id>NCT00531427</nct_id>
  </id_info>
  <brief_title>Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled With Open-label Run-in Assessing Efficacy, Tolerability,Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects w/Moderate to Severe, Chronic Pain Due to OA of Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the analgesic efficacy and safety of
      Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve
      subjects with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. The
      double-blind treatment intervention duration is 12 weeks, during which time supplemental
      analgesic medication (immediate-release oxycodone for the first 6 days postrandomization and
      acetaminophen or ibuprofen for the remainder of the double-blind phase) will be provided to
      all subjects in addition to study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical
      experience indicating it to be safe and effective in a variety of therapeutic settings for
      the relief of moderate to severe pain. BTDS is a transdermal system formulation that is
      designed to deliver a consistent and a steady dose of buprenorphine over a 7-day period with
      limited blood concentration fluctuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Average Pain Over the Last 24 Hours&quot; Score of the Study Knee at Week 12 of the Double Blind Phase.</measure>
    <time_frame>24 hours (week 12)</time_frame>
    <description>&quot;Average pain over the last 24 hours&quot; scores of the study knee at week 12 was evaluated on an 11-point scale: 0 = no pain, 10 = worst pain imaginable, recorded daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Subjects were permitted to take sponsor-provided supplemental analgesic medication after week 1 of the double-blind treatment (acetaminophen or ibuprofen).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase.</measure>
    <time_frame>Weeks 4, 8, and 12 of the double-bind phase</time_frame>
    <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">567</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal system 10 and 20 applied for 7-day wear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal system to match BTDS patches, applied for 7-day wear</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>transdermal system 10 and 20 applied for 7-day wear</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>transdermal system (placebo) applied for 7-day wear</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with moderate to severe chronic osteoarthritis (OA) pain of the knee (lasting
             several hours daily) as their predominant pain condition,

          -  clinical diagnosis of OA of the knee 1 year or longer,

          -  subjects treated within the 14 days prior to screening with nonopioid therapy only, or
             with therapy including opioids at a dose of &lt; 5 mg oxycodone (or equivalent) per day,

          -  subjects whose OA knee pain is not adequately controlled with nonopioid analgesic
             medication and who the investigator feels are appropriate candidates for
             around-the-clock opioid therapy.

        Exclusion Criteria:

          -  subjects who have had arthroscopy on either knee or hip within 6 months of entering
             the study or open surgery on either knee or hip within 9 months of entering the study,

          -  subjects who are allergic to buprenorphine or who have a history of allergies to other
             opioids,

          -  subjects who have allergies or other contraindications to transdermal delivery systems
             or patch adhesives.

        Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pain Management</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458-7200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Royal Palm</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Flor</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR Research Associates</name>
      <address>
        <city>Bogart</city>
        <state>Georgia</state>
        <zip>30622-6821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dawsonville</city>
        <state>Georgia</state>
        <zip>30534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814-4526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Association of IN</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graves-Gilbert Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat-Lab I, Inc.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New Iberia</city>
        <state>Louisiana</state>
        <zip>70563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Clinical Research</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830-6141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Internal Medicine</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sports Med Consultants PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Morgantown</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Endoscopy Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Mt. Gilead</city>
        <state>Ohio</state>
        <zip>43338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-8311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Clinical Research</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <zip>15017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oyster Point Family Health Ctr</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic, PLLC</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Nederland</city>
        <state>Texas</state>
        <zip>77627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205-1116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NDC Medical Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independence Family Medicine</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Northwest Primary Care</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>July 28, 2010</results_first_submitted>
  <results_first_submitted_qc>August 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2010</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain,</keyword>
  <keyword>OA of the knee,</keyword>
  <keyword>opioid,</keyword>
  <keyword>transdermal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27-Sep-2007 (first patient first visit) to 28-Apr-2009 (last patient last visit) at 83 medical/research sites in US</recruitment_details>
      <pre_assignment_details>Open-label run-in period designed to select those subjects who both tolerated and responded to treatment with BTDS 10 or BTDS 20 (an enriched design). N = 1151 entered the run-in period, and N = 571 completed. One subject was not dosed, therefore N = 570 randomized. N = 3 subjects did not have safety data, therefore N = 567 had double-blind data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double-blind BTDS 10 or 20</title>
          <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="P2">
          <title>Double-blind Placebo</title>
          <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double-blind BTDS 10 or 20</title>
          <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="B2">
          <title>Double-blind Placebo</title>
          <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="282"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="567"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="9.75"/>
                    <measurement group_id="B2" value="59.1" spread="9.77"/>
                    <measurement group_id="B3" value="59.1" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>&quot;Average Pain Over the Last 24 Hours&quot; Score of the Study Knee at Week 12 of the Double Blind Phase.</title>
        <description>&quot;Average pain over the last 24 hours” scores of the study knee at week 12 was evaluated on an 11-point scale: 0 = no pain, 10 = worst pain imaginable, recorded daily.</description>
        <time_frame>24 hours (week 12)</time_frame>
        <population>The full analysis population is the group of subjects who were randomized and received at least 1 dose of double-blind study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 10 or 20</title>
            <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo</title>
            <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Average Pain Over the Last 24 Hours&quot; Score of the Study Knee at Week 12 of the Double Blind Phase.</title>
          <description>&quot;Average pain over the last 24 hours” scores of the study knee at week 12 was evaluated on an 11-point scale: 0 = no pain, 10 = worst pain imaginable, recorded daily.</description>
          <population>The full analysis population is the group of subjects who were randomized and received at least 1 dose of double-blind study drug</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="1.340"/>
                    <measurement group_id="O2" value="7.06" spread="1.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization (Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="1.292"/>
                    <measurement group_id="O2" value="2.74" spread="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-blind Week 12 (Visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="2.644"/>
                    <measurement group_id="O2" value="4.22" spread="2.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>[Week 12 analysis] The null hypothesis was “no group differences.” The alternative hypothesis was that BTDS arm was superior to the placebo arm.
Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0853</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Statistics are based on a mixed effect general linear model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.</title>
        <description>Subjects were permitted to take sponsor-provided supplemental analgesic medication after week 1 of the double-blind treatment (acetaminophen or ibuprofen).</description>
        <time_frame>10 weeks</time_frame>
        <population>Subjects in the full analysis population who took at least 1 dose of supplemental analgesic medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 10 or 20</title>
            <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo</title>
            <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.</title>
          <description>Subjects were permitted to take sponsor-provided supplemental analgesic medication after week 1 of the double-blind treatment (acetaminophen or ibuprofen).</description>
          <population>Subjects in the full analysis population who took at least 1 dose of supplemental analgesic medication.</population>
          <units>tablets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.701" spread="0.8139"/>
                    <measurement group_id="O2" value="0.740" spread="0.8566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Categorical analysis P value is based on a Fisher's exact test. Mean daily number of tablets for subjects who took &lt;=1 dose of supplemental analgesia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7098</p_value>
            <p_value_desc>To control multiplicity and family-wise error rate, a gate-keeping strategy (stepwise approach) was used to evaluate the statistical significance of the secondary variables. If the primary is negative, the secondary P values are descriptive only.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment as a factor and screening and pre-randomization mean pain as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.233</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase.</title>
        <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
        <time_frame>Weeks 4, 8, and 12 of the double-bind phase</time_frame>
        <population>Full Analysis Population (N = 570) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 10 or 20</title>
            <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo</title>
            <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase.</title>
          <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
          <population>Full Analysis Population (N = 570) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.51" spread="24.790"/>
                    <measurement group_id="O2" value="51.23" spread="25.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.23" spread="19.583"/>
                    <measurement group_id="O2" value="26.04" spread="20.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.22" spread="23.086"/>
                    <measurement group_id="O2" value="35.08" spread="25.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.46" spread="23.795"/>
                    <measurement group_id="O2" value="34.78" spread="24.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.60" spread="25.177"/>
                    <measurement group_id="O2" value="33.63" spread="25.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weeks 4, 8, 12 analysis The sleep disturbance subscale was analyzed using the mixed effect linear model with fixed effects for treatment (BTDS or placebo) and time (weeks 1, 2, 4, 8, 12) as categorical, screening mean and prerandomization mean value as covariates, and subject as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>To control multiplicity and family-wise error rate, a gate-keeping strategy (stepwise approach) was used to evaluate the statistical significance of the secondary variables. If the primary is negative, the secondary P values are descriptive only.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.44</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) that occurred after the signing of the informed consent up to end of study and 7 days after discontinuation; or Serious AEs occurring up to 30 days following the last study visit were followed until resolution or for up to 30 days.</time_frame>
      <desc>AEs were obtained through spontaneous reports and subject interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind BTDS</title>
          <description>Buprenorphine transdermal patches (BTDS) 10 or 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="E2">
          <title>Double-blind Placebo</title>
          <description>Placebo patches to match the BTDS patches applied for 7-day wear</description>
        </group>
        <group group_id="E3">
          <title>Open-label Run-in Period</title>
          <description>The open-label run-in period was designed with duration of time sufficient to select those subjects who both tolerated and responded to treatment with BTDS 10 or BTDS 20 (an enriched design). During this period, subjects were required to discontinue use of all nonstudy drugs used for the treatment of chronic pain and no supplemental analgesic medications were allowed. Subjects who did not tolerate BTDS 5 were discontinued from the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery - DEATH</sub_title>
                <description>DEATH Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Systematic and nonsystematic assessment One subject experienced bradycardia poststudy</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease - DEATH</sub_title>
                <description>DEATH Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Systematic and nonsystematic assessments One subject experienced acute myocardial infarction poststudy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <description>Poststudy SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Noncardiac chest pain</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac procedure complications</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Poststudy SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>Poststudy SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <description>Poststudy SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="520" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="242" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="1151"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader, Executive Medical Director</name_or_title>
      <organization>Purdue Pharma</organization>
      <phone>800-733-1333</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

